Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00081913
Other study ID # 00165
Secondary ID
Status Completed
Phase Phase 1
First received April 26, 2004
Last updated January 23, 2008
Start date January 2004
Est. completion date June 2006

Study information

Verified date January 2008
Source Losordo, Douglas, M.D.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if cell therapy with your own cells (autologous cells) delivered with a catheter to regions of the heart with poor blood flow will be safe and if it will relieve your chest pain and/or your ability to exercise.


Description:

The goal of this study is to determine the safety of various doses of autologous (one's own) stem cells, delivered with a catheter into the regions of the heart with poor blood flow. Stem cells are primitive cells produced by bone marrow that can develop into blood cells or other types of cells. In addition to determining whether this new approach is safe, the diagnostic tests may offer preliminary insights into the usefulness of this approach for treating myocardial ischemia (the condition where areas in the heart are lacking enough oxygen and blood flow to keep the heart muscle working well).

This is a blinded, randomized study to compare a certain type of stem cell called CD34-positive versus a placebo agent (normal saline). You will have a 3:1 chance of receiving your CD34-positive stem cells versus the placebo agent (normal saline). You will not know whether you received the CD34-positive cells or the placebo agent (normal saline). If you are randomized to receive placebo (normal saline), you will undergo all of the pre-treatment phases of this study (including the stem cell mobilization phase and the apheresis procedure), but rather than receiving injections of CD34-positive cells, you will receive injections of the placebo agent (normal saline). There is some research evidence that suggests CD34-positive cells may help develop new blood vessels or improve blood flow when injected directly into the heart muscle.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date June 2006
Est. primary completion date March 2006
Accepts healthy volunteers No
Gender Both
Age group 21 Years and older
Eligibility Inclusion Criteria:

- Subjects with functional class (CCS) III or IV angina.

- Subjects who have attempted "best" medical therapy without control of symptoms.

- All subjects must have a recent coronary angiogram (within the last 3 months).

- Clinical signs and symptoms of clinically significant ischemia on nuclear perfusion imaging.

- Subjects must be able to complete a minimum of 1 minute but no more than 6 minutes of the Standard Bruce Protocol.

- Subject experiences angina during the baseline exercise tolerance test.

- Subjects must either be no longer capable of reproduction or taking acceptable measures to prevent reproduction during the study.

- Normal renal function.

- Normal liver function.

- Normal blood count.

Angiographic Inclusions:

- Total occlusion of an epicardial coronary artery.

- Candidates at high risk for percutaneous coronary angioplasty of treatment zone(s) based upon clinical or anatomic considerations including but not limited to the following: diabetes, congestive heart failure (severe right heart failure, NYHA class III or IV), left main disease, pulmonary hypertension, severe proximal vessel tortuosity, severe bendpoint obstructions, diffuse disease (>2 cm in length), small vessel (<2 mm reference diameter), stenosis which are either diffuse (>2 cm in length) or distal, incessant restenosis lesions, unfavorable bifurcation stenosis, and degenerated or thrombosed saphenous vein grafts.

Exclusion Criteria:

- Predominant congestive heart failure symptoms.

- Patients who have been hospitalized with a primary diagnosis of CHF in the prior 6 months.

- Patients who have had diuretics added to their medical regimen or an increase in diuretic dosage for signs or symptoms of CHF in the past 6 months.

- Patients with a left ventricular ejection fraction of less than 25% as determined by transthoracic echocardiography.

- Patients with physical findings consistent with ongoing uncontrolled CHF.

- Myocardial infarction within 30 days of treatment.

- Successful coronary revascularization procedures within 3 months of study enrollment.

- Documented stroke or transient ischemic attack (TIA) within 60 days of study enrollment.

- History of severe aortic stenosis or insufficiency; severe mitral stenosis; or severe mitral insufficiency.

- Severe co-morbidity associated with a reduction in life expectancy of less than 1 year.

- Subjects with PT, PTT or platelet counts greater than the upper limit of normal and those with a hematocrit <35%.

- Subjects with uncontrolled hypertension.

- Currently enrolled in another investigational device or drug trial (IDE or IND) that has not completed the required follow-up period.

- History of alcohol or drug abuse within 3 months of screening.

- Joint or peripheral vascular disease that severely limits treadmill walking.

- Chronic obstructive pulmonary disease that severely limits walking or FEV1.0<30% predicted.

- Subjects who are pregnant or lactating.

- Males and females who are capable of reproduction and will not take acceptable measures to prevent reproduction during the study.

- Subjects who test positive for HIV, hepatitis B or hepatitis C, have a chronic inflammatory disease, autoimmune disease or are on chronic immunosuppressive medications.

- Subjects with a known hypersensitivity to E. coli-derived proteins.

- Subjects with evidence (clinical, laboratory, or imaging) of cancer recurrence within the past 5 years (other than non-melanoma skin cancer or in situ cervical carcinoma).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment


Intervention

Genetic:
Cell Therapy - Autologous CD34 Positive Cells


Locations

Country Name City State
United States Caritas St. Elizabeth's Medical Center Boston Massachusetts
United States Scripps Clinic La Jolla California
United States Minneapolis Heart Institute Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Losordo, Douglas, M.D.

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Completed NCT04153006 - Comparison of Fingerstick Versus Venous Sample for Troponin I.
Completed NCT01205776 - EXCEL Clinical Trial N/A
Active, not recruiting NCT04555174 - BIOFLOW-VIII All-comers Orsiro Mission Safety and Performance Registry
Recruiting NCT04582877 - Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial N/A
Recruiting NCT04390672 - Multivessel TALENT N/A
Recruiting NCT03265535 - Validation of a Single Rest-Stress Imaging Protocol for Myocardial Perfusion Imaging
Not yet recruiting NCT04522583 - Increased CRP Concentrations in Patients Admitted to the Emergency Department With Troponin Elevation Aids to Rule Out Coronary Ischemia
Completed NCT02554006 - Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings N/A
Terminated NCT02407626 - Optimization of Cardioprotection in Diabetic Patients Undergoing Cardiac Surgery N/A
Completed NCT02510547 - Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial Phase 4
Active, not recruiting NCT02189499 - Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent Phase 2
Completed NCT02197065 - Pilot Study of Atorvastatin for Orthopedic Surgery Patients Phase 2
Completed NCT02264717 - Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease N/A
Recruiting NCT01681381 - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization N/A
Completed NCT01655043 - Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI Phase 2
Terminated NCT01892917 - BIOFLOW-III Hungary Satellite Registry N/A
Completed NCT01679886 - Comparison of Rubidium PET and SPECT With CZT Crystals for Detection of Myocardial Ischemia in Overweighed Patients and Women N/A
Completed NCT02707445 - Genotyping Influences Outcome of Coronary Artery Stenting N/A